Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07317505 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
A Phase 1 study of Cancer and Cancer (Solid Tumors), sponsored by Conjupro Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 270
- Enrollment target
- 3
- Study locations
NCT07317505: Recruiting Phase 1 study of Cancer and Cancer (Solid Tumors), sponsored by Conjupro Biotherapeutics.
NCT07317505 is a Phase 1 study of Cancer and Cancer (Solid Tumors) that is actively recruiting participants, run by Conjupro Biotherapeutics. The registered enrollment target is 270 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07317505, a Phase 1 study of Cancer and Cancer (Solid Tumors), is actively recruiting participants, sponsored by Conjupro Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 270 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacodynamic (PD) characteristics of JMT108 * To explore the correlation between biomarker levels and preliminary efficacy Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive JMT108 by intravenous injection every 2 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years
Primary Outcome
To evaluate the safety and tolerability of JMT108 to determine the dose and schedule to be used in phase 1b.
Conditions Studied
Interventions
- DRUG JMT108
Study Locations (3)
North Carolina
- Carolina BioOncology Institute - Huntersville
Texas
- NEXT Dallas - Dallas
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
What NCT07317505 shows while recruiting
NCT07317505 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which JMT108 is the first listed.
NCT07317505 reports a single indexed study location in North Carolina, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07317505 about?
NCT07317505 is a clinical study titled "A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors". The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose ...
What is the current status of trial NCT07317505?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2025-12-02. Estimated completion is 2029-09.
What conditions does trial NCT07317505 study?
This clinical trial studies the following conditions: Cancer, Cancer (Solid Tumors).
What interventions are being tested in trial NCT07317505?
The interventions under investigation include: JMT108 (DRUG).
Who is sponsoring clinical trial NCT07317505?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07317505 being conducted?
This trial has 3 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07317505's enrollment target sits among peer trials
270 197th of 615 higher than 419 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI